Celgene Corp sales and marketing update

The U.K.’s NICE issued final guidance recommending against use of Imnovid pomalidomide from Celgene in combination with dexamethasone to treat relapsed and refractory multiple myeloma (MM). NICE said analyses by Celgene showed that the thalidomide analog did not offer sufficient benefit to justify its high price. The decision is in line with the preliminary appraisal issued in October (see BioCentury, Oct. 20, 2014). ...